A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
End-stage liver disease from non-malignant cirrhosis — what the hospice team must understand on day one about a disease that kills like cancer but rarely gets named like one.
Cirrhosis is the irreversible end-stage of chronic hepatic fibrosis — the architectural replacement of functional liver parenchyma with scar tissue that cannot be regenerated. The liver loses its capacity to perform its approximately 500 known metabolic functions simultaneously: protein synthesis (albumin, clotting factors), bile production, ammonia metabolism, drug detoxification, glucose homeostasis, and immune function. When the liver fails, every organ system fails with it — the kidneys through hepatorenal physiology, the brain through ammonia accumulation, the coagulation system through loss of both procoagulant and anticoagulant factor production, the vascular system through portal hypertension-driven collateral formation and variceal development.[2]
The hospice clinician caring for ESLD walks into a disease with a prognosis as grave as many late-stage malignancies but without the social and medical permission that cancer gives to dying. Cirrhosis is not called cancer. Its cause — for 40–50% of cases — is called alcoholism, not fate. The prognosis is rarely communicated with the directness that oncologists bring to a stage IV conversation. Families arrive at hospice enrollment confused, unprepared, and sometimes angry. The patient may carry shame about the diagnosis. The hospice NP's first clinical act is often not a medication review — it is the honest naming of what is happening.[4]
Decompensation is the clinical turning point — the transition from compensated cirrhosis (preserved hepatic function despite fibrosis) to decompensated cirrhosis (overt complications of portal hypertension and hepatic insufficiency). The first decompensation event — ascites, variceal hemorrhage, hepatic encephalopathy, or spontaneous bacterial peritonitis — marks the beginning of the hospice-relevant clinical phase. Median survival after first decompensation is approximately 2 years; after second or third decompensation, median survival is often less than 1 year. The hospice-eligible ESLD patient has typically experienced multiple decompensation events and is not recovering to the prior functional baseline between them.[3]
Three features make ESLD uniquely challenging in hospice: (1) Stigma. Alcohol-related liver disease carries a cultural burden that no other terminal diagnosis imposes in the same way — the patient's family may be grieving the disease and angry about the drinking simultaneously. The hospice clinician must be prepared to hold space for both without judgment. (2) Episodic lethality. Variceal hemorrhage can be immediately fatal, arriving without warning. The crisis plan must be in the home before the bleed happens — not after. (3) Cognitive dissolution before death. Hepatic encephalopathy progressively replaces the patient's personality with confusion, agitation, and unresponsiveness. The family experiences the loss of the person before the loss of the body. This is ambiguous loss — profound, underprepared for, and different from any other terminal trajectory.
Cirrhosis diagnosis, prognostic staging, and what to extract from prior records at hospice enrollment. Most patients arrive with an established diagnosis — this section helps you read it accurately and use it clinically.
Cirrhosis diagnosis methods the hospice clinician will encounter in prior records:
Extract these data points at enrollment — they define the clinical trajectory and inform every management decision:
Your loved one's liver disease was diagnosed through a combination of blood tests, imaging scans, and possibly a liver biopsy. The most important number at this stage is the MELD score — a formula calculated from three blood tests that predicts how serious the liver disease is. The hospice team uses this score to understand the prognosis and plan care. You do not need to calculate it — your hospice clinician will explain what it means for your family member's situation. What matters most now is not refining the diagnosis — it has already been established — but focusing on the comfort and quality of whatever time remains.
El equipo de hospicio utiliza el puntaje MELD para entender el pronóstico. Lo más importante ahora es el comfort y la calidad del tiempo que queda.
Cirrhosis etiology and the specific dimensions — clinical, ethical, and psychosocial — that matter at end of life. Relevant for family conversations, stigma navigation, and answering "why did this happen?"
This question arrives at almost every ESLD family meeting, and the answer matters more than any medication adjustment. For alcohol-related liver disease: alcohol use disorder is a medical condition with genetic, neurobiological, and social determinants — not a moral failure. The research is clear that vulnerability to addiction is as heritable as many medical diseases. The stigma attached to this diagnosis is not proportionate to the moral reality of how it developed. For metabolic liver disease: this grew from processes in the body's metabolism over decades — processes that are influenced by genetics, food environment, and medical access, not simply choices. For autoimmune and hereditary causes: this was written in the biology from the beginning. Whatever the cause, the person you are caring for did not deserve this. And you did not deserve this either.
For patients with hereditary hemochromatosis (HFE C282Y/C282Y), alpha-1 antitrypsin deficiency (PiZZ phenotype), or Wilson's disease: first-degree family member genetic testing is clinically indicated even during the patient's hospice enrollment. Identifying a sibling or child with early hemochromatosis before cirrhosis develops can prevent their death entirely with simple phlebotomy treatment. A genetic counseling referral initiated at the hospice enrollment visit for the identified family members — not for the enrolled patient — is one of the highest-yield population health interventions in all of palliative medicine. Document the discussion and referral in the clinical note.
Comfort-directed management of the major complications of decompensated cirrhosis. Each complication below has distinct mechanisms, distinct management, and distinct goals at hospice enrollment.
ESLD management in hospice is complication management. Unlike oncology, where the hospice question is primarily whether to continue disease-directed treatment, ESLD hospice is defined by active, ongoing management of multiple simultaneous organ-system complications — each requiring specific pharmacological, procedural, and educational intervention. The hospice NP caring for ESLD must be competent in the management of at minimum six concurrent clinical syndromes: ascites, hepatic encephalopathy (HE), esophageal varices, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and coagulopathy. Each is detailed below. Additionally, cholestatic pruritus and nutritional management require specific attention that is frequently omitted in standard hospice practice.[18]
The mechanism of ascites formation in cirrhosis is multifactorial: (1) portal hypertension drives sinusoidal hypertension and splanchnic vasodilation via nitric oxide overproduction; (2) hypoalbuminemia reduces oncotic pressure, favoring transudation into the peritoneum; (3) RAAS activation (renin-angiotensin-aldosterone system) causes renal sodium and water retention — the fundamental driver of fluid accumulation. At ESLD, the ascites is essentially irreversible without liver transplantation. Diagnostic paracentesis (SAAG calculation): SAAG ≥1.1 g/dL confirms portal hypertension as the cause. Ascitic fluid cell count >250 PMNs/mm³ diagnoses SBP regardless of culture result.[19]
The failing liver cannot metabolize ammonia generated from intestinal protein catabolism and bacterial nitrogen production. Ammonia and other nitrogenous waste products cross the blood-brain barrier, causing astrocyte swelling, cerebral edema, and the progressive neurological dysfunction that defines HE.[21]
West Haven Criteria (HE grading):
Common HE precipitants to identify and address: Constipation (most common — target 2–4 soft stools/day with lactulose), GI bleeding (protein load from digested blood), infection/SBP, dehydration/over-diuresis, hyponatremia, sedating medications (benzodiazepines, opioids at excessive doses), hypokalemia, dietary protein excess, TIPS complications.[22]
Portal hypertension drives blood through portosystemic collateral vessels — including the submucosal veins of the esophagus and gastric cardia. When these thin-walled varices rupture, massive hematemesis can be immediately fatal. First variceal hemorrhage carries a 20–30% in-hospital mortality. Rebleeding within 6 weeks in untreated patients: approximately 60%. Beta-blocker prophylaxis (propranolol, nadolol) and variceal band ligation reduce but do not eliminate this risk.[27]
Hospice-specific management — establish the crisis plan at enrollment, not after the bleed:
SBP is bacterial infection of ascitic fluid in the absence of a surgically treatable intra-abdominal source. The classic triad (fever, abdominal pain, altered mental status) is present in fewer than 50% of cases — the ascitic abdomen is relatively insensate, pain is often muted, and fever may be absent in immunocompromised cirrhotic patients. The most common presenting feature is unexplained hepatic encephalopathy or a general deterioration without obvious cause.[29]
HRS is functional renal failure in the setting of cirrhosis and ascites — caused by severe splanchnic vasodilation and compensatory renal vasoconstriction, in the absence of structural renal disease. The kidneys are intrinsically normal — they fail because the systemic circulation cannot maintain adequate renal perfusion. HRS type 1 (acute, rapidly progressive): median survival without liver transplant is below 4 weeks. HRS type 2 (chronic, moderate): associated with refractory ascites and poor prognosis but slower progression.[31]
The cirrhotic liver simultaneously loses the capacity to synthesize both procoagulant factors (II, V, VII, IX, X) and anticoagulant factors (protein C, protein S, antithrombin). The INR measures only procoagulant factor activity and rises as the liver fails — but this rise does not accurately predict clinical bleeding risk because anticoagulant capacity is equally impaired. Cirrhotic patients have "rebalanced hemostasis" — a fragile coagulation equilibrium that is not captured by the INR.[32]
Cholestatic pruritus — itching caused by bile salt accumulation in the skin from cholestatic liver disease (particularly PBC, PSC, and advanced cholestatic cirrhosis) — is among the most severe and debilitating symptoms in all of hepatology. It is poorly responsive to antihistamines (which do not address the underlying bile salt-mediated mechanism) and requires specific treatment with agents that most hospice clinicians have not prescribed before.[34]
Malnutrition and sarcopenia in ESLD are near-universal and are independent predictors of mortality — worse prognosis than MELD alone in several studies. The failing liver has impaired glycogen storage; patients effectively enter a prolonged fasting state overnight because the liver cannot maintain glucose homeostasis between meals. This produces protein catabolism and accelerated muscle wasting with every overnight fast.[36]
Comfort-directed treatments that should be actively pursued, maintained, or initiated at hospice enrollment for ESLD — these are not "disease-directed therapy" but the specific interventions that preserve quality of life, prevent catastrophic complications, and allow the patient to remain the person their family recognizes for as long as possible.
Unlike oncological hospice — where "when therapy makes sense" often means when to consider additional cycles of chemotherapy — ESLD hospice asks a different question: which of the many active, ongoing comfort-directed interventions specific to decompensated cirrhosis have been initiated, optimized, and planned for? The following criteria represent the clinical actions that should be completed at or before the end of the first hospice visit.[18]
Interventions that are not comfort-compatible in ESLD hospice — contraindicated, futile, or actively harmful at end stage. Knowing what to stop and what to never start is as clinically essential as knowing what to prescribe.
ESLD patients are significantly under-referred to palliative care and hospice relative to their prognosis and symptom burden. Studies consistently show that patients with cirrhosis and MELD scores above 20 receive palliative care at far lower rates than oncology patients with equivalent prognoses — despite similar or worse symptom burden and shorter median survival. Barriers include physician prognostic uncertainty, the episodic nature of ESLD (which creates intermittent hope), ongoing transplant candidacy in some patients, and the absence of a clear "cancer diagnosis" that socially validates hospice referral.[38] The following identifies interventions that are not clinically appropriate in comfort-goals ESLD patients at hospice enrollment — each with a specific reason that the hospice NP can communicate to the patient, family, and any consulting clinicians.
Data from Poonja et al. (2014) and Walling et al. (2008) document that patients with ESLD receive significantly fewer palliative care consultations than oncology patients with equivalent MELD-predicted mortality, despite equivalent or greater symptom burden. The median time from first decompensation to death is approximately 24 months; the median duration of hospice enrollment for ESLD patients who do enroll is often less than 3 weeks — meaning most patients reach hospice in the final days rather than the final months. The hospice NP who encounters an ESLD patient with MELD above 20 or Child-Pugh Class C in a primary care, hepatology, or hospitalist follow-up context should initiate or strongly recommend a palliative care referral — this is earlier-stage advocacy that can prevent the pattern of enrolling ESLD patients when they have days, not weeks or months, of life remaining.[38] When speaking with referring physicians or patients about hospice eligibility: ESLD does not need to be cancer for hospice to be appropriate. The Medicare hospice eligibility criteria for ESLD (MELD >17 with two or more of the listed complications) are specific, documented, and equivalent in prognostic validity to Stage IV cancer eligibility criteria. Use the specific language of MELD scores and the two-complication threshold to make the eligibility case clearly.
Evidence-graded integrative, interventional, and complementary approaches specific to ESLD hospice — many routinely omitted from cirrhosis care plans. Grade A = RCT-level; B = multi-observational/meta-analysis; C = limited clinical or strong observational; D = expert opinion.
Several of these approaches represent evidence-based interventions that are routinely withheld from cirrhosis patients despite strong trial data — particularly rifaximin for hepatic encephalopathy and albumin infusion beyond its SBP indication. Others are integrative approaches with a genuine evidence base that can improve quality of life and symptom burden when standard pharmacotherapy is insufficient. Review the grade for each and pursue patient assistance programs aggressively for expensive items (rifaximin, albumin).
ESLD creates the most dangerous supplement landscape in all of hospice medicine. Evidence grading, safe options, dosing, drug interaction flags, and explicit contraindications specific to end-stage liver disease. The failing liver cannot be "supported" by supplements — but it can be harmed by them.
At every ESLD hospice visit, ask directly: "Are you taking any vitamins, herbs, teas, or supplements — including things bought at the health food store, online, or given by family?" Apply the single overriding question to every supplement identified: Does this supplement have hepatotoxic potential or significant hepatic drug interaction? For most herbal supplements, the answer is yes. The supplement regimen in ESLD must be as minimal as possible. Every supplement added to a failing liver is a risk calculation, not a wellness decision.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Zinc (acetate or sulfate) | Grade B | 220 mg BID (zinc sulfate) or equivalent elemental zinc 50 mg/day; take with food to reduce nausea | HE adjunct — zinc deficiency is universal in cirrhosis from reduced hepatic storage, malabsorption, and urinary losses; zinc is a cofactor for urea cycle enzymes; deficiency impairs ammonia detoxification; multiple RCTs (Reding et al., Takuma et al.) show reduced HE frequency and severity with supplementation[33] | No hepatotoxicity at standard doses; safe across Child-Pugh classes A–C; available OTC at low cost; nausea if taken on empty stomach; zinc sulfate, gluconate, and picolinate all acceptable; do not exceed 50 mg elemental zinc/day — excess zinc impairs copper absorption and can cause immunosuppression |
| Probiotics (multi-strain) | Grade B | Multi-strain preparation (e.g., VSL#3, Lactobacillus + Bifidobacterium blends) 1–2 capsules/day; refrigerated products preferred for viability | Gut microbiome modulation — probiotics alter intestinal bacterial composition, reducing ammoniagenic bacteria and gut-derived endotoxin contributing to HE and systemic inflammatory activation; meta-analyses show modest reduction in overt HE events and minimal adverse effects[34] | Generally safe in cirrhosis at standard probiotic doses; theoretical risk of bacteremia in severely immunocompromised patients (Child-Pugh C with prior SBP) — use clinical judgment; no significant hepatotoxicity; do not use live bacteria products in patients with active SBP or active gastrointestinal bleeding; discontinue if fever develops |
| Vitamin D (cholecalciferol D3) | Grade B | 1,000–4,000 IU/day PO D3; correct frank deficiency (25-OH vitamin D below 20 ng/mL) before maintenance; check 25-OH vitamin D level at enrollment if labs are available | Vitamin D deficiency is nearly universal in cirrhosis (70–90% prevalence) from impaired hepatic 25-hydroxylation, malabsorption, and reduced sun exposure; deficiency worsens muscle weakness, bone disease, and immune dysfunction; correction is associated with reduced infection risk and improved muscle strength in observational studies[35] | No hepatotoxicity at standard replacement doses (up to 4,000 IU/day); vitamin D is fat-soluble and requires bile acid absorption — cholestatic patients may have reduced absorption; megadose vitamin D (above 10,000 IU/day) can cause hypercalcemia; no significant drug interactions at standard doses; hepatic 25-hydroxylation is impaired in cirrhosis — 1,25-OH vitamin D (calcitriol) may be more effective but requires physician supervision |
| Branched-Chain Amino Acids (BCAA) | Grade B | BCAA granules or oral solution 12–14 g/day in 2–3 divided doses; commercial products: Fresubin Hepa, Aminoleban EN, NutrHep oral powder; combine with late evening snack protocol for synergistic effect | BCAA supplementation corrects the elevated AAA:BCAA ratio that contributes to HE pathophysiology; multiple RCTs and Cochrane meta-analysis support reduction in HE frequency, improved protein-energy nutritional status, and reduced muscle wasting (sarcopenia) in cirrhosis; sarcopenia is an independent mortality predictor in ESLD[36] | No hepatotoxicity; safe across all Child-Pugh classes; well-tolerated; may cause mild GI symptoms initially (nausea, bloating — usually transient); may modestly improve blood glucose control in diabetic cirrhosis patients — monitor glucose if concurrent diabetes; no significant drug interactions; can be added to food, smoothies, or yogurt for palatability |
| L-Carnitine | Grade C | L-carnitine 1–2 g/day PO; levocarnitine preferred; may be combined with zinc and BCAA in nutritional support protocol | Carnitine deficiency is common in cirrhosis from impaired hepatic synthesis; L-carnitine plays a role in fatty acid mitochondrial transport and energy metabolism; small RCTs suggest L-carnitine supplementation may reduce blood ammonia levels, improve HE symptoms, and reduce fatigue in cirrhosis — with a plausible mechanism and acceptable safety profile[37] | No hepatotoxicity at standard doses; generally well-tolerated; may cause mild GI upset; fish-odor syndrome (trimethylaminuria) can occur in rare patients; no significant hepatic drug interactions at standard doses; theoretical interaction with anticoagulants (modest antiplatelet effect reported in some studies — monitor INR if on anticoagulation, though INR is not a reliable clotting guide in cirrhosis); discontinue if GI symptoms are intolerable |
A guide, not a prediction. The ESLD trajectory is characterized by episodic decompensation events — each raising the MELD score and accelerating the arc — punctuated by background progressive hepatic dysfunction. The patient and family must understand both the gradual and the sudden.
Non-malignant cirrhosis does not follow the gradual linear trajectory of most cancer diagnoses. It follows an episodic pattern — a period of compensated function followed by the first decompensation event (ascites, variceal bleed, hepatic encephalopathy, SBP), then partial recovery, then progressively less complete recovery between increasingly frequent decompensation events, until the MELD score crosses 25–30 and multi-organ failure begins to dominate the clinical picture.[38] The hospice-enrolled patient is typically on their second or third major decompensation event. Two equally possible death trajectories must be named for the family: (1) gradual progressive decline over weeks to months from accumulating organ failure — the "expected" hospice death; and (2) sudden catastrophic death from massive variceal hemorrhage or acute-on-chronic liver failure — the death that can arrive at 2 AM without warning. Families must be prepared for both. The timeline below describes the background trajectory from which either death may emerge.[39]
Every ESLD hospice family must be told, before any crisis, that there are two ways this disease ends: the gradual decline described in this timeline, and the sudden catastrophic variceal hemorrhage that can arrive without warning and is immediately life-threatening. Families who know this in advance are frightened but prepared. Families who experience massive hematemesis at 2 AM without preparation experience preventable trauma. Name both trajectories. Write the plan. Leave the medications. Review the plan at every visit.
Symptom-targeted pharmacology specific to end-stage liver disease from non-malignant cirrhosis. What to have in the comfort kit, what to adjust for hepatic impairment, and what the evidence supports for ESLD-specific symptom management.
| Drug | Class / Target | Starting Dose / Route | Notes / Cautions |
|---|---|---|---|
| Lactulose | Osmotic laxative / Hepatic Encephalopathy | 30 mL PO BID–QID; titrate to 2–4 stools/day | The bowel frequency target is the clinical management guide — not the dose. Titrate to achieve 2–4 soft stools daily. Liquid lactulose for dysphagia. Lactulose enema (300 mL in 700 mL water, retained) for patients unable to take oral medications in acute HE. Constipation is an HE precipitant — document stool frequency at every visit. Can cause abdominal cramping and bloating; reduce dose temporarily if intolerable, but do not stop. |
| Rifaximin | Non-absorbable antibiotic / Hepatic Encephalopathy prevention | 550 mg PO BID | PREVENT trial (Bass 2010 NEJM): rifaximin + lactulose reduced overt HE recurrence from 46% to 22% vs. lactulose alone over 6 months. Add at enrollment for any patient with prior HE episodes. Reduces intestinal ammonia-producing bacteria without systemic absorption. Pursue manufacturer patient assistance (Salix Pharmaceuticals) if cost is a barrier. Rifaximin is expensive (~$1,200/month without coverage). Patient assistance available. Document PREVENT trial basis in chart. |
| Zinc sulfate | Micronutrient / Hepatic Encephalopathy adjunct | 220 mg PO BID with meals | Zinc deficiency is near-universal in cirrhosis (reduced hepatic storage, malabsorption, urinary losses). Zinc is a urea cycle cofactor; deficiency impairs ammonia detoxification. Grade B evidence for reduction in HE frequency in RCTs (Reding 1984, Takuma 2010). No hepatotoxicity risk at standard doses. This is one of the few supplements that is safe and beneficial in ESLD — prescribe it. OTC zinc sulfate or gluconate. May cause mild GI upset — take with food. |
| Spironolactone | Aldosterone antagonist / Ascites | 100 mg PO daily (with furosemide 40 mg, 5:2 ratio) | First-line diuretic for ascites. Maximum dose 400 mg/day. Maintain 5:2 spironolactone:furosemide ratio to prevent hyperkalemia. Target: 0.5 kg/day weight loss (no edema), 1 kg/day (with edema). Hold if K+ >5.5 mEq/L. Monitor electrolytes at enrollment and periodically. ⚠ Hold if K+ >5.5 mEq/L or creatinine rising significantly (potential HRS trigger). |
| Furosemide | Loop diuretic / Ascites (adjunct) | 40 mg PO daily (with spironolactone 100 mg) | Adjunct to spironolactone; dose-escalated in 5:2 ratio. Maximum 160 mg/day. Hold or reduce if creatinine rising — over-diuresis is a common HRS trigger. For refractory ascites with HRS risk, paracentesis is preferred over dose escalation. Monitor BMP at each dose escalation. ⚠ Over-diuresis precipitates HRS. When ascites is refractory, paracentesis is safer than escalating furosemide beyond 160 mg/day. |
| Fentanyl transdermal | Opioid / Pain, Dyspnea | 12 mcg/hr patch q72h (hepatic-adjusted starting dose) | Preferred opioid in ESLD. Fentanyl is hepatically metabolized to norfentanyl (inactive). Half-life prolonged in severe hepatic impairment — start low, assess carefully. Transdermal onset 12–24h; use IR opioid for breakthrough while titrating. Avoid in opioid-naive patients — titrate from oral opioids first. Do not use in opioid-naive ESLD patients without oral titration first. Transdermal absorption variable with significant ascites. |
| Morphine (reduced dose) | Opioid / Pain, Dyspnea | 1–2.5 mg PO q6–8h PRN (25–50% standard dose) | Use only if fentanyl or hydromorphone unavailable. Morphine-6-glucuronide (M6G) accumulates in hepatic impairment and precipitates HE. If used, start at 25–50% of standard dose, extend interval to q6–8h, titrate slowly, and monitor carefully for HE precipitation. Avoid morphine in concurrent renal impairment. ⚠ M6G accumulation risk. Monitor for HE precipitation with every dose escalation. Hydromorphone or fentanyl preferred. |
| Hydromorphone | Opioid / Pain, Dyspnea | 0.5–1 mg PO q6–8h PRN (hepatic-adjusted) | Alternative preferred opioid in ESLD. Glucuronidated to hydromorphone-3-glucuronide (H3G, neuroexcitatory) — use with caution in concurrent renal impairment. In pure hepatic failure without renal failure, hydromorphone is a reasonable alternative to fentanyl at reduced dose. Start at 25–50% of standard dose. Preferred over morphine in ESLD. Use with caution if creatinine rising — H3G accumulates in renal impairment. |
| Midazolam | Benzodiazepine / Variceal hemorrhage crisis, Terminal agitation, Refractory symptoms | 2.5–5 mg SQ/IV PRN; CSCI 10–30 mg/24h for refractory | Must be drawn and at the bedside before variceal hemorrhage occurs. For massive variceal hemorrhage crisis: midazolam 5 mg SQ/IM immediately, morphine/hydromorphone for comfort, family support. For terminal agitation: midazolam CSCI. For refractory symptoms: palliative sedation context. Hepatic impairment prolongs half-life — use lowest effective dose. ⚠ Have drawn and labeled in the home before the hemorrhage crisis. This is the medication that makes a terrifying death a peaceful one. |
| Lorazepam | Benzodiazepine / Anxiety, Acute agitation | 0.5 mg PO/SQ q6–8h PRN; reduce by 50% in ESLD | Use at 50% of standard dose in ESLD due to prolonged half-life. Reserve for acute anxiety episodes — avoid scheduled use unless breakthrough is frequent. Hepatic impairment significantly prolongs lorazepam half-life; accumulation risk with scheduled dosing. Distinguish HE-driven agitation (treat HE) from anxiety (treat with lorazepam). ⚠ Benzodiazepines can precipitate or worsen HE. Use the minimum effective dose. Distinguish HE agitation from anxiety before prescribing. |
| Ondansetron | 5-HT3 antagonist / Nausea | 4 mg PO/SL q8h PRN | Preferred antiemetic in ESLD. Less dopaminergic side effects than haloperidol or metoclopramide. Reduce dose in severe hepatic impairment (max 8 mg/dose). Avoid metoclopramide in ESLD — extrapyramidal effects more common with dopamine antagonists in liver failure. Maximum single dose 8 mg in severe hepatic impairment. QTc prolongation monitoring if used long-term. |
| Haloperidol | Antipsychotic / HE agitation, Nausea | 0.5 mg PO/SQ q8–12h; reduce dose in ESLD | Use at reduced dose (50% of standard) in ESLD. Useful for HE-related agitation when HE management is optimized and agitation persists. Also effective for nausea. Monitor for extrapyramidal effects, which are more common in liver failure. Do not use as first-line for delirium before treating HE precipitants. Distinguish HE agitation (treat with lactulose/rifaximin optimization first) from anxiety/delirium requiring haloperidol. |
| Mirtazapine | NaSSA antidepressant / Depression, Anorexia, Pruritus, Insomnia | 7.5–15 mg PO QHS | Multi-indication benefit in ESLD hospice: addresses depression, insomnia, anorexia (via antihistamine appetite stimulation), and cholestatic pruritus. Faster onset than SSRIs in the terminal population. Start at 7.5 mg QHS. Hepatically metabolized — use lowest effective dose. No known HE precipitation risk at standard doses. Addresses 4 symptoms simultaneously. Sedating at low dose (7.5 mg) — paradoxically less sedating at higher doses. Start at 7.5 mg for maximal sedation/appetite effect. |
| Cholestyramine | Bile acid sequestrant / Cholestatic pruritus | 4 g PO BID–QID, before and after meals; mix in water or juice | First-line for cholestatic pruritus. Binds bile acids in the intestinal lumen, reducing their systemic recirculation. Must be taken 1 hour before or 4–6 hours after all other medications — bile acid binding impairs absorption of fat-soluble vitamins and all other oral drugs. If bile duct obstruction is complete, cholestyramine will be ineffective (no bile reaching intestine to bind). ⚠ Separate from ALL medications by 1–4 hours. Impairs fat-soluble vitamin absorption. Ineffective if complete biliary obstruction. |
| Rifampicin (rifampin) | Rifamycin antibiotic / Cholestatic pruritus (off-label) | 150–300 mg PO BID | Second-line for cholestatic pruritus unresponsive to cholestyramine. Mechanism: CYP induction altering bile acid metabolism; opioid receptor modulation. Grade B evidence (Ghent 1988 RCT). Hepatotoxicity risk requires ALT monitoring at baseline and 4–6 weeks; avoid if already severely elevated transaminases. Not for long-term use in advanced cirrhosis without close monitoring. ⚠ Hepatotoxic potential — monitor ALT. CYP3A4 inducer with multiple drug interactions. Limit use to 6 weeks initially; reassess. |
| Norfloxacin | Fluoroquinolone antibiotic / SBP secondary prophylaxis | 400 mg PO daily (prophylaxis) | Secondary SBP prophylaxis for patients with prior SBP episode — reduces recurrence rate from 68% to 20% at 1 year (Ginès 1990). Also primary prophylaxis for high-risk patients (ascitic protein <1.5 g/dL with MELD ≥15 or renal dysfunction). Consistent with hospice comfort goals when preventing SBP recurrence is a shared goal. Stop if patient develops multi-drug resistant organism. SBP recurrence is a major source of suffering (fever, abdominal pain, HE precipitation). Secondary prophylaxis is a comfort measure. |
| TMP-SMX | Sulfonamide antibiotic / SBP prophylaxis (alternative) | 160/800 mg PO 5 days/week | Alternative to norfloxacin for SBP secondary prophylaxis when norfloxacin unavailable or cost is a barrier. Comparable efficacy data. Use with caution in sulfonamide-allergic patients. Monitor potassium (TMP blocks renal potassium excretion — additive with spironolactone). ⚠ Additive hyperkalemia risk with spironolactone. Monitor K+ when both prescribed. |
| Ceftriaxone | Third-generation cephalosporin / SBP treatment | 2 g IV/SQ daily for 5 days (SBP treatment) | First-line antibiotic for SBP treatment when IV access is feasible or comfort-directed IV therapy is consistent with goals. Ceftriaxone can be administered subcutaneously with appropriate dilution if IV access unavailable. Pair with IV albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 to prevent HRS development following SBP — this albumin dosing is Grade A evidence (Sort 1999 NEJM). Always pair SBP treatment with albumin infusion to prevent HRS. Consider home IV antibiotics when consistent with goals of care. |
| Albumin 20% | Plasma protein / Post-paracentesis, SBP treatment, Volume depletion | 6–8 g per liter drained (post-LVP >5L); 1.5 g/kg Day 1, 1 g/kg Day 3 (SBP) | Multi-indication in ESLD. (1) Post-LVP: albumin infusion at 6–8 g per liter drained for paracenteses draining >5 liters prevents post-paracentesis circulatory dysfunction (PPCD) — hemodynamic collapse from rapid fluid redistribution. (2) SBP treatment: albumin prevents HRS development — Grade A evidence (Sort 1999). (3) Systemic circulatory dysfunction in severe decompensated cirrhosis: anti-inflammatory and antioxidant effects beyond oncotic pressure. Albumin infusion is a comfort measure in ESLD — preventing HRS and PPCD prevents acute suffering from renal failure and hemodynamic instability. |
| Propranolol / Nadolol | Non-selective beta-blocker / Variceal hemorrhage prophylaxis | Propranolol 20 mg PO BID–TID; Nadolol 40 mg PO daily (titrate to HR 55–60) | Non-selective beta-blockers reduce portal pressure and variceal hemorrhage risk — continue at enrollment if already prescribed. Propranolol or nadolol for primary and secondary variceal hemorrhage prophylaxis. Target resting heart rate 55–60 bpm. Hold if SBP <90 mmHg, bradycardia, or renal failure (HRS context). In early ESLD, benefit is clear; in very advanced ESLD with refractory ascites (CHESS effect), stop-beta-blocker should be discussed with team. ⚠ Discontinue if SBP <90, bradycardia, or HRS develops. In refractory ascites, beta-blockers may worsen circulatory dysfunction — discuss with hepatology. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN; or 0.6–1.2 mg/24h CSCI | Preferred over hyoscine (scopolamine) in conscious patients — glycopyrrolate does not cross the blood-brain barrier and has no CNS effects. Reduces oropharyngeal and bronchial secretions at end of life. Family teaching: "This sound is not distressing to your loved one — the noise sounds much worse than it feels." Reposition and gentle oral suctioning as adjuncts. No CNS effects preferred in ESLD patients with HE risk. Glycopyrrolate is the agent of choice in ESLD over scopolamine. |
| Acetaminophen | Non-opioid analgesic / Pain | 325–500 mg PO q6–8h PRN; maximum 2 g/day in ALD | The only safe non-opioid analgesic in ESLD (NSAIDs absolutely contraindicated). Standard acetaminophen doses are safe in non-alcoholic cirrhosis at up to 2 g/day. In alcohol-related liver disease, limit to 2 g/day maximum — chronic alcohol use induces CYP2E1 increasing toxic metabolite formation. Regular moderate doses are safe in ALD; high doses are not. Document 2 g/day limit explicitly in chart. ⚠ Maximum 2 g/day in alcohol-related liver disease. Standard doses are safe in non-alcoholic cirrhosis. Do not withhold — it is the only safe non-opioid analgesic available. |
| Vitamin K | Fat-soluble vitamin / Coagulopathy assessment | 10 mg PO daily × 3 days (diagnostic/therapeutic trial) | Limited utility in advanced cirrhosis — the elevated PT/INR reflects synthetic failure, not vitamin K deficiency, in most patients. A 3-day trial of vitamin K 10 mg PO daily may identify the small subset with concurrent vitamin K deficiency (malnutrition, cholestasis with fat malabsorption). If PT does not improve after 3 days of vitamin K, no benefit from continuation. INR is unreliable as a clotting guide in cirrhosis — rebalanced hemostasis; see S11. Diagnostic trial only. If PT does not respond in 3 days, stop — the coagulopathy is hepatic synthetic failure, not vitamin K deficiency. |
High-yield clinical pearls for the hospice team managing end-stage liver disease from non-malignant cirrhosis. The things you learn at the bedside of enough ESLD patients. Not in the textbook.
The existential, relational, and spiritual dimensions of dying from end-stage liver disease — including the stigma of alcohol, the grief of encephalopathy-related personality change, transplant grief, and the specific family conflict that no other hospice diagnosis produces in quite the same way.
End-stage liver disease from non-malignant cirrhosis produces a psychosocial burden that is both more complex and more stigmatized than most other hospice diagnoses. The patient may carry shame about the disease's cause. The family may carry anger about the years of drinking and the disease that resulted. The personality and behavior changes of hepatic encephalopathy create a specific grief — the loss of the person before the death of the body — that has no parallel in other diseases. The liver failure patient who arrives at hospice without a cancer diagnosis arrives without the social permission that cancer gives to dying. Their hospice clinician must do more than manage symptoms. They must name what is happening, hold what is difficult, and refuse the stigma that has surrounded this patient for years.
Depression affects 24–34% of patients with decompensated cirrhosis (Nardelli et al.) and is systematically underdiagnosed. Distinguish depression from fatigue and somatic symptoms of liver failure — PHQ-9 somatic items (fatigue, sleep, appetite) are confounded by ESLD itself. Use cognitive-affective items: hopelessness, worthlessness, guilt, suicidal ideation.
The patient with alcohol-related cirrhosis arrives at hospice carrying a cultural and social stigma that no other terminal diagnosis imposes in the same way. Alcoholism has been treated as a character failure rather than a medical condition with genetic, neurobiological, and social determinants. The family may carry years of anger about the drinking, the broken promises, the consequences that accumulated. The patient may carry shame — not just about the drinking, but about the disease it caused, and about the fact that they are dying of something the world will call "self-inflicted."
The hospice clinician's role is not to adjudicate the moral complexity of the family's history. It is to provide excellent end-of-life care to a person who is dying of a terminal illness, and to make space for all of the grief in the room — the patient's shame, the family's anger, the collective loss of what the drinking cost — without imposing premature forgiveness as a clinical expectation.
"Alcohol use disorder is a medical condition with genetic, neurobiological, and social determinants that are as real as any other disease. The blame that has been attached to this diagnosis is disproportionate to the moral reality. What happened in your family with alcohol is more complex than any single person's willpower or lack of it. What matters now is that someone you love is dying, and that you are here."
The family watching a person they love become confused, aggressive, sexually inappropriate, or completely unrecognizable during HE episodes is experiencing ambiguous loss in its most acute clinical form: the body is alive, the eyes are open, but the person they know is intermittently or permanently absent. Pauline Boss's ambiguous loss framework — the loss that cannot be mourned because it is not yet complete — is the exact grief of the family with a cirrhotic parent in HE.
The husband who said things during an encephalopathy episode that he would never say, who did not recognize his wife of 40 years, who was later returned by lactulose and rifaximin to himself — and who is now terrified of the next episode — is experiencing a grief that the hospice team must name explicitly. "What your husband does and says during hepatic encephalopathy is not him. It is the disease. He cannot control it, and it does not reflect how he feels about you when he is well."
"I want to make sure we talk about what you're experiencing when your loved one has these episodes of confusion. There's a name for it — it's called ambiguous loss, the grief of losing someone who is still here. It's one of the hardest things in medicine to witness. You're not alone in feeling it, and you don't have to pretend you're not."
Use the FICA framework (Faith/beliefs, Importance, Community, Address) at enrollment. Ask: "What gives you strength during this time?" ESLD adds specific spiritual complexity: guilt and moral injury are common, especially in patients who identify their drinking as the cause of their family's suffering. These are not psychological problems — they are spiritual ones that require the expertise of a skilled chaplain, not a clinical intervention.
Passive wish for death ("I'm ready to go — I've had enough") is common in ESLD and existentially appropriate after years of suffering. It is not the same as active suicidal ideation. In ALD hospice, assess carefully for guilt-driven active suicidal ideation: the patient who believes they deserve to die because of harm caused by their drinking is at elevated risk. Distinguish: passive wish for death (common, appropriate, deserves compassionate acknowledgment), active suicidal ideation with intent (requires immediate psychiatric engagement and safety planning), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol).
Plain language for families caring for someone with end-stage liver disease at home. Share, print, or read aloud at the bedside.
You are caring for someone whose liver is no longer able to do the work it needs to do to keep the body in balance. Liver failure produces some of the most visible and challenging symptoms in all of medicine — the swollen abdomen, the yellow skin, the confusion that comes and goes, the fear of bleeding. These symptoms can be frightening. They can also be managed. The hospice team is here to help you manage each one — and to support you, not just your loved one, through what comes next.
If your loved one has alcohol-related liver disease, you may be carrying a history of conflict and pain alongside your grief. All of that is real. You do not have to resolve it to be present and to provide good care. Being here is enough.
Blood vomiting or dark material from the mouth (coffee grounds appearance): This is a variceal hemorrhage emergency — follow the crisis plan, administer comfort medications as instructed, call the nurse immediately. Sudden worsening confusion or inability to rouse your loved one: May indicate acute severe HE or SBP — needs same-day assessment. Fever above 38.5°C (101.3°F) with abdominal pain or new confusion: Possible SBP — needs same-day evaluation and antibiotic treatment. Breathing difficulty that is not relieved by sitting up or fan use: May indicate rapid ascites accumulation or pulmonary fluid — call the nurse for assessment and possible paracentesis. Agitation, combativeness, or unsafe behavior during a confusion episode: Escalating HE — call for guidance on comfort medications and safety. Decreased urination for 12+ hours with worsening leg swelling: May indicate hepatorenal syndrome development — needs assessment. Any situation that feels like a medical emergency: Do not hesitate to call. We would rather hear from you ten times unnecessarily than miss a situation where early intervention would have helped.
🙏 You are doing something that matters profoundly. Research consistently shows that patients who have people present and engaged in their care are more comfortable and more at peace. You are not a bystander to this disease — you are part of the care team. The love and presence you bring to this bedside is medicine that we cannot prescribe. Be here. It is enough. And when you need support — for yourself, not just for your loved one — please ask. We are here for you too.
Clinical field wisdom from 12+ years at the bedside of ESLD patients. Not guidelines — real. What you learn after doing enough of these.
Peer-reviewed citations organized by clinical category. PMIDs hyperlinked. Evidence levels assigned by study type. Based on articles retrieved from PubMed.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.